Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Q1 2023 Earnings Presentation
15 slides from Bonesupport Holding Ab's earnings presentation, Apr 27, 2023
Slide 1: BONESUPPORT Q1 (2023) Report
BONESUPPORT Q1 (2023) Report April 27th , 2023 Emil Billbäck, CEO Håkan Johansson, CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: BONESUPPORT – First quarter report 2023
BONESUPPORT – First quarter report 2023 Q1 2023: • Net sales SEK 119,7 m, growth: +80% versus Q1 2022, (+66% in constant exchange rates, CER) • Operating result (before incentive provisions): SEK 4.6 m (SEK -12,5 m) • Reported EBIT: SEK 0,8 m (SEK -16,5 m) • Strong sales development with CERAMENT G
Slide 4: Accelerated market penetration. Largest Q-over-Q net growth
Accelerated market penetration. Largest Q-over-Q net growth LTM Quarterly Sales per Segment 383 400 Incremental, 400 375 375 Q-over-Q 350 329 350 LTM growth: 325 325 300 287 300 Q2-22 23 MSEK 275 257 275 Q3-22 30 MSEK 250 234 250 Q4-22 42 MSEK Net Sales, SEK m Net Sales, SEK m 225 213 225 197205 Q1-
Slide 5: North America: Expansion of customer base and launch of CERAMENT G
North America: Expansion of customer base and launch of CERAMENT G Q1 2023 • Sales of SEK 85,9 m, growth of 109% over Q1 2022, growth of 87% in constant exchange rate, CER • Sales in Q1 2023 represented a reported sequential growth of 17% over Q4 2022 • CERAMENT BVF grew with 23% in Q1 2023 over Q1
Slide 6: CERAMENT G launched in the US
CERAMENT G launched in the US Market penetration dynamics: Contracts/ Hospital system Surgeon Q1 2023 sales CERAMENT G in US: SEK 35 m listings approvals promotion Since introduction (Q4 22 – Q1 23): SEK 49 m Group Purchasing Hospital groups: i.e. Training Trial Evaluation Regular use Organization:
Slide 7: EUROW: Gradual recovery in general surgical procedures
EUROW Gradual recovery in general surgical procedures Q1 2023 • Sales of SEK 33,8 m, growth of 34% vs Q4 2021, +32% in constant exchange rates, CER • Steady recovery of general procedure volumes versus Q3 and Q4. • Health care staffing shortage remains challenging, as capacity is still 5-8% below pr
Slide 8: Financial Report
BONESUPPORT Q1 (2023) Report Financial Report
Slide 9: Q1 2023 net sales SEK 119,7 m
Q1 2023 net sales SEK 119,7 m SEK m • NA: 109 percent reported growth. 87 percent growth in CER • EUROW: 34 percent reported growth. 32 percent growth CER • High impact from currency movements 9
Slide 10: Gross Margin: North America and EUROW
North America +109% EUROW +34% (+87% CER) (+32% CER) Net sales Net sales Q1-23 Q1-23 North America 2023 2022 EUROW 2023 2022 SEK m Q1-23 Q4-22 Q3-22 Q2-22 Q1-22 SEK m Q1-23 Q4-22 Q3-22 Q2-22 Q1-22 Net Sales 85,9 73,4 56,3 46,0 41,2 Net Sales 33,8 29,8 28,3 28,6 25,2 Gross profit 81,6 69,4 53,1 42,9
Slide 11: Q1 expenses growth driven by marketing and sales promotion activities
Q1 expenses growth driven by marketing and sales promotion activities Key Figures 2023 2022 2021 SEK m Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Selling expenses 49,0 46,8 38,8 37,4 35,2 35,4 33,1 32,5 Sales Commissions and fees 29,9 28,1 21,1 16,8 14,3 13,9 11,8 10,5 Research and Development expenses 12,5 14,8 12,6
Slide 12: A SEK 17 m underlying profit improvement
A SEK 17 m underlying profit improvement Key Figures 2023 2022 2021 SEK m Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Net Sales 119,7 103,2 84,6 74,6 66,3 61,4 54,9 51,8 Gross Margin (%) 90,5 91,5 90,8 89,0 90,5 89,3 89,0 89,5 Operating Profit/Loss 0,8 -19,3 -13,9 -14,9 -16,5 -21,8 -13,3 -25,9 Adj. Operating profit (i)
Slide 13: Clear Corporate Strategy Driving Value Creation
BONESUPPORT Q1 (2023) Report Clear Corporate Strategy Driving Value Creation
Slide 14: BONESUPPORT – exciting journey ahead
BONESUPPORT – exciting journey ahead • CERAMENT G (Gentamicin) launched in the US T R E AT M E N T P R E F E R E N C E – Clinical superiority to standard of care 92% – Strong Hospital System Approval and pilot-use – Addresses an immediate and unmet clinical need 92% of US orthopedic surgeons – Only
Slide 15: Q&A
BONESUPPORT Q1 (2023) Report Q&A